In a phase I clinical trial conducted by Feng et al., 11 patients with advanced HER2-positive CCA were treated with cyclophosphamide and paclitaxel followed by HER2-targeted CAR-T cells with moderate results (one patient with partial response and five patients with stable disease) [46]. The gene discussed is ERBB2; the disease is cholangiocarcinoma.